---
title: "REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -1.13"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/239193983.md"
datetime: "2025-05-07T20:15:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/239193983.md)
  - [en](https://longbridge.com/en/news/239193983.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/239193983.md)
generator: "portal-rs"
---

# REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -1.13

EPS: As of FY2025 Q1, the actual value is USD -1.13.

### Segment Revenue

-   **Research and Development Expenses**: $205.7 million for the three months ended March 31, 2025, compared to $118.0 million for the same period in 2024, representing a 74% increase.
-   **General and Administrative Expenses**: $35.0 million for the three months ended March 31, 2025, compared to $22.8 million for the same period in 2024, representing a 53% increase.

### Operational Metrics

-   **Net Loss**: $213.4 million for the three months ended March 31, 2025, compared to $116.0 million for the same period in 2024.
-   **Loss from Operations**: $240.8 million for the three months ended March 31, 2025, compared to $140.9 million for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $194.4 million for the three months ended March 31, 2025, compared to - $160.6 million for the same period in 2024.
-   **Net Cash Used in Investing Activities**: - $15.9 million for the three months ended March 31, 2025, compared to - $248.0 million for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $0.9 million for the three months ended March 31, 2025, compared to $0.8 million for the same period in 2024.

### Unique Metrics

-   **Stock-Based Compensation Expense**: $25.1 million for the three months ended March 31, 2025, compared to $16.2 million for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: Revolution Medicines, Inc. plans to advance its RAS(ON) inhibitors, including daraxonrasib, elironrasib, and zoldonrasib, through clinical development with ongoing and planned Phase 3 trials. The company expects to initiate pivotal combination studies in 2026.
-   **Non-Core Business**: The company is exploring collaborations, such as with Aethon Therapeutics, Inc. and Tango Therapeutics, Inc., to enhance its research and development efforts.

### Related Stocks

- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [Oil set for second weekly rise as unsettled US-Iran war crimps supply](https://longbridge.com/en/news/296555193.md)
- [IREN Just Passed Its Biggest AI Test as Microsoft and Nvidia Bet Billions](https://longbridge.com/en/news/296533962.md)
- [Google Is Reportedly Working with AMD for Its New TPU. What This Means for AMD Stock.](https://longbridge.com/en/news/296528134.md)
- [Trump Boosted INTC and DELL: Now He Says ‘Do Magnets’—Are MP and USAR Stocks Next?](https://longbridge.com/en/news/296591886.md)
- [Why Iovance Biotherapeutics Stock Hit 52-Week High](https://longbridge.com/en/news/296522969.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**